作者
Loïc Verlingue,Antoîne Italiano,Hans Prenen,Eva Maria Guerra Alía,Diego Tosi,Ruth Perets,Iwona Ługowska,Vladimir Moiseyenko,Mahmut Gümüş,Çağatay Arslan,Colin R. Lindsay,Sanjeev Deva,Álvaro Taus,Ana Oaknin,Sylvie Rottey,İrfan Çiçin,Sema Sezgin Göksu,A. Yu. Smolin,Susana Roselló-Keränen,Christin Habigt,Daniel Marbach,Christophe Boetsch,David Dejardin,Nassim Sleiman,Stefan Evers,Muriel Richard,Caroline Ardeshir,Jehad Charo,Anton Kraxner,Volker Teichgräber,Nino Keshelava,Rafał Dziadziuszko
摘要
Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in recurrent and/or metastatic cervical squamous cell carcinoma (SCC) in a phase 2 basket study (NCT03386721).
不配.
Singularity
shinysparrow
爱静静
浅尝离白
元谷雪
8R60d8
Henry
kento
寻道图强
zyfqpc
tuanheqi
一一
AireenBeryl531
HEIKU
iNk
Hayat
老肖
云瑾
rosalieshi
皖公网安备34019202002308
